Advisory - Unauthorized health product "Psychotic'' by Insane Labz may pose serious health risks
OTTAWA, Aug. 10, 2017 /CNW/ -
Issue Health Canada is advising Canadians that the unauthorized pre-workout supplement "Psychotic" by "Insane Labz" may pose serious health risks. Health Canada laboratory testing found high levels of caffeine and other stimulant ingredients (hordenine, huperzine and arecoline) not listed on the label. The product was sold by retailers in Ontario and Quebec.
Who is affected
Consumers who have bought or used "Psychotic" by Insane Labz
Affected products
"Psychotic" by Insane Labz
What consumers should do
Stop using this product. Consult with your health care professional if you have used it and have health concerns.
Read product labels to verify that health products have been authorized for sale by Health Canada. Authorized health products have an eight-digit Drug Identification Number (DIN), Natural Product Number (NPN) or Homeopathic Drug Number (DIN-HM). You can also check whether products have been authorized for sale by searching Health Canada's Drug Product Database and Licensed Natural Health Product Database.
Report adverse events to health products to Health Canada by calling toll-free at 1?866?234?2345, or by reporting online, by mail or by fax.
Report complaints about health products to Health Canada by calling toll-free at 1?800?267?9675, or complete an online complaint form.
Background High levels of caffeine and the other stimulant ingredients found in the product (hordenine, huperzine and arecoline) can cause serious side effects ranging from dizziness, tremors, headaches and irregularities in heart rate to seizures, psychosis, heart attacks and stroke. In addition, caffeine consumption by pregnant women is linked to a variety of negative birth outcomes such as spontaneous abortion, pre-term delivery, birth defects, and delayed fetal growth or delayed development following birth.
What Health Canada is doing At Health Canada's request, the distributor, Nutri-Genics, has confirmed that it has stopped selling the product. Health Canada requested that the company initiate a recall. Should additional retailers or distributors be identified, Health Canada will take appropriate action and inform Canadians as necessary.
The global gastroesophageal reflux disease (GERD) market size is estimated to grow by USD 879.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 3.2% during the forecast period. Rising geriatric...
Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of...
Imperial Tobacco Canada Limited ("ITCAN") has officially submitted its feedback to Health Canada regarding the proposed Ministerial Order on nicotine replacement therapy products (NRTs). ITCAN strongly believes that NRTs, especially innovative...
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...